PROM1 and ovarian carcinoma: In this current study we demonstrate that niclosamide not only targets the Wnt pathway, but it also targets the mTOR and the STAT3 pathways and specifically targets CD133+ CSCs and chemoresistant cells isolated from a PDX ovarian cancer model.